News

CGeneTech was selected as a finalist in the 7th China Innovation and Entrepreneurship Competition for Biomedical Industry

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-11-14
  • Views:0

(Summary description)The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

CGeneTech was selected as a finalist in the 7th China Innovation and Entrepreneurship Competition for Biomedical Industry

(Summary description)The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

  • Categories:Company News
  • Author:admin
  • Origin:
  • Time of issue:2018-11-14
  • Views:0

The 7th China Innovation and Entrepreneurship Competition Biopharmaceutical Industry Finals was held in Guangzhou from November 12-15, 2018. The event is the ultimate competition of biomedical innovation power in the national finals, and will also build a state-level platform for the integration and development of resources from all sides in Guangzhou. Biomedicine is known as the "crown jewel" of the new round of technological revolution. In the national "treasure" on the road, hundreds of billions of emerging industries are rising, leading to the vigorous development of the health industry. Nowadays, there are many innovative ventures in the biomedical industry, and a large number of new biomedical stars have emerged from the competition.

The strength of biomedical finalists in this year's national finals is not to be underestimated. There are 3667 biomedical companies among more than 30,000 participating companies nationwide, and they have been selected through local preliminary, final and final rounds, and finally 235 outstanding companies have advanced to Guangzhou, among which, the number of finalists from Yunnan, Shanghai, Guangdong and Jiangsu are the most. From the perspective of the projects, innovative devices, precision medicine, genetic testing, new drug research and development, regenerative medicine, medical equipment, in vitro diagnostics, Internet + medical technology and other fields will be on the same stage to show technology.

Participating companies will compete in the "semi-finals + finals" promotion pathway, the semi-finals and finals will be held on November 14 and 15, respectively. The semi-finals will be promoted by group competition, and all finalists will be divided into 3 start-up groups and 7 growth groups for group roadshow. 8 minutes of project roadshow and 7 minutes of Q&A interaction will constitute the whole competition. The semi-finals will evaluate 101 outstanding companies, and at the same time determine the top 6 start-ups and top 14 growing companies in the country, leading to the final competition for the crown. The first, second and third prizes in the national biomedical field will be awarded at the final round.
*** Translated with www.DeepL.com/Translator (free version) ***

Team CGeneTech, represented by Pan Huiping, excelled in the finals and won the National Excellence Award in the 2018 Innovation and Entrepreneurship Competition. Coinciding with today's United Nations Diabetes Day, we have been on our way as an innovative company leading the way with the development of hypoglycemic drugs.

In fact, the predecessor of the United Nations Diabetes Day (World Diabetes Day' WDD) was co-sponsored by the World Health Organization and the International Diabetes Federation in 1991, with the aim of causing global awareness and awakening to diabetes.

At the end of 2006, the United Nations adopted a resolution to change the name of World Diabetes Day to United Nations Diabetes Day from 2007 onwards, elevating expert and academic actions to governmental actions in all countries, and urging governments and all sectors of society to strengthen the control of diabetes and reduce the risk of diabetes. The United Nations adopted a resolution at the end of 2007 to formally rename World Diabetes Day as "United Nations Diabetes Day", which elevates expert and academic actions to the actions of national governments, prompting governments and all sectors of society to strengthen the control of diabetes and reduce its harmful effects.

 

目前,盛世泰科已与包括江苏省人民医院在内的机构达成协议,开展磷酸盛格列汀的Ⅰ期临床试验。磷酸盛格列汀属于二肽基肽酶(DPP)-4抑制剂类药物,此类药物最大的优势是不会引起低血糖和体重增加,且具有心血管保护作用;同时,由于中国2型糖尿病患者的胰岛β细胞受损程度比欧美患者更严重,而DPP-4抑制剂类药物的特点之一是可以改善β细胞受损,因而中国患者能更多地获益,这使得DPP-4抑制剂类药物在中国越来越受到医生的认可。


 磷酸盛格列汀是国家“十二五”和“十三五”重大新药创制专项和江苏省“科技支撑计划”专项,是完全自主研发的糖尿病新药。磷酸盛格列汀的临床前研究显示,其有效性是全球最优药物磷酸西格列汀(捷诺维)的3-10倍,安全性是磷酸西格列汀的5倍以上,优势十分明显。磷酸盛格列汀的成功上市,将为数亿中国2型糖尿病患者带来一种更加实惠和安全有效的药物选择,并将进一步提高我国2型糖尿病的治疗水平。盛世泰科将始终以自主创新作为企业发展的源动力,继续承担中国重大疾病新药研发的使命,与国内外学术力量紧密合作,积极开拓中国医药科技产业化的发展之路,造福中国广大患者。

The

The listing application of Shengshi Tyco's new hypoglycemic drug Shenggliptin was accepted

Today, Shengshi Tyco has accepted the marketing application (NDA) of Shenggliptin, a DPP-4 inhibitor, submitted to the National Drug Administration (NMPA) for the treatment of type 2 diabetes.
2023-02-02
Quantity

"Quantity" Half Achieves Double Prosperity: Tyco's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.
2022-10-17

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO